Advertisement
Screener

Elite Pharmaceuticals, Inc. (ELTP) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

2.8 / 5 stars · 68/120 Roast Me

Elite Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

Elite Pharmaceuticals, Inc. (ELTP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 81.00% for the 12-month period ending 2024-03-31, per its 10-K filed 2025-06-30.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2025-06-30

  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2018-06-30 was 123.00%, a 1.15% increase year-over-year.
  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2017-06-30 was 121.60%.
  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2024 was 81.00%, a 1.25% increase from fiscal 2023.
  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 80.00%.
  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2018 was 123.00%, a 1.65% increase from fiscal 2017.
  • Elite Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2017 was 121.00%, a 0.83% increase from fiscal 2016.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month
2024-03-3181.00%
10-K · filed 2025-06-30
2023-12-3181.00%
10-Q · filed 2024-02-14
2023-03-3180.00%
10-K · filed 2024-07-01
2018-06-30123.00%
10-Q · filed 2018-08-09
2018-03-31123.00%
10-K · filed 2019-06-21
2017-12-31123.00%
10-Q · filed 2018-02-09
2017-09-30123.20%
10-Q · filed 2017-11-09
2017-06-30121.60%
10-Q · filed 2017-08-09
2017-03-31121.00%
10-K · filed 2018-06-14
2016-12-31121.00%
10-Q · filed 2017-02-09
2016-09-30121.00%
10-Q · filed 2016-11-09
2016-03-31120.00%
10-K · filed 2018-06-14
2015-03-31121.00%
10-K · filed 2017-06-14